ContraFect is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of antibiotic-resistant infections. Co.'s primary product candidate, exebacase, for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis. In addition to bacteremia, Staphylococcus aureus is also a common cause of pneumonia and osteomyelitis as well as biofilm-associated infections of heart valves, indwelling devices and catheters. Co.'s product candidate, CF-370, is designed to target a gram -negative bacteria including Pseudomonas aeruginosa. The CFRX stock yearly return is shown above.
The yearly return on the CFRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CFRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|